Reuters logo
BRIEF-Zafgen announces positive topline phase 1 data for ZGN-1061
2017年5月4日 / 晚上8点41分 / 6 个月前

BRIEF-Zafgen announces positive topline phase 1 data for ZGN-1061

May 4 (Reuters) - Zafgen Inc

* Zafgen announces positive topline phase 1 data for ZGN-1061, a second generation METAP2 inhibitor

* Zafgen Inc says improvements in metabolic parameters and trends for weight loss supportive of drug effect

* Zafgen Inc says clinical trial shows weight loss trends of up to one pound per week and an early favorable safety and tolerability profile

* Zafgen Inc says ZGN-1061 was well-tolerated and safe, with no evidence of prothrombotic effects Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below